Superiority of amino-modified chiral mesoporous silica nanoparticles in delivering indometacin

References

• Xie M, Shi H, Li Z, et al. A multifunctional mesoporous silica nanocomposite for targeted delivery, controlled release of doxorubicin and bioimaging. Colloids Surf B Biointerfaces. 2013;110:138–147.
   PubMed Web of Science ®Google Scholar
• Li J, Du X, Zheng N, et al. Contribution of carboxyl modified chiral mesoporous silica nanoparticles in delivering doxorubicin hydrochloride in vitro: pH-response controlled release, enhanced drug cellular uptake and cytotoxicity. Colloids Surf B Biointerfaces. 2016;141:374–381.
   PubMed Web of Science ®Google Scholar
• Li J, Xu L, Yang B, et al. Biomimetic synthesized chiral mesoporous silica: Structures and controlled release functions as drug carrier. Mater Sci Eng C. 2015;55:367–372.
   PubMed Web of Science ®Google Scholar
• Li J, Xu L, Zheng N, et al. Biomimetic synthesized bimodal nanoporous silica: bimodal mesostructure formation and application for ibuprofen delivery. Mater Sci Eng C. 2016;58:1105–1111.
   PubMed Web of Science ®Google Scholar
• Fangqiong Tang LL, Chen D. Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery. Adv Mater. 2012;24:1504–1534.
   PubMed Web of Science ®Google Scholar
• Mamaeva V, Sahlgren C, Linden M. Mesoporous silica nanoparticles in medicine–recent advances. Adv Drug Deliv Rev. 2013;65:689–702.
   PubMed Web of Science ®Google Scholar
• He Q, Jianlin S. Mesoporous silica nanoparticle based nano drug delivery systems: synthesis, controlled drug release and delivery, pharmacokinetics and biocompatibility. J Mater Chem. 2011;21;5845–5855.
   Web of Science ®Google Scholar
• Ahmadi Nasab N, Hassani Kumleh H, Beygzadeh H, et al. Delivery of curcumin by a pH-responsive chitosan mesoporous silica nanoparticles for cancer treatment. Artif Cell Nanomed Biotechnol. 2017. DOI:10.1080/21691401.2017.1290648
   PubMed Web of Science ®Google Scholar
• Han L, Che S. Anionic surfactant templated mesoporous silicas (AMSs). Chem Soc Rev. 2013;42:3740–3752.
   PubMed Web of Science ®Google Scholar
• Che S, Liu Z, Ohsuna T, et al. Synthesis and characterization of chiral mesoporous silica. Nature. 2004;429:281–284.
   PubMed Web of Science ®Google Scholar
• Ng E-P, Bahaman N, Mukti RR, et al. Detailed kinetic observation revealing the formation mechanism of chiral mesoporous silica (CMS) synthesized by cooperative self-assembly of anionic chiral surfactant. Mater Res Bull. 2015;62:192–199.
   Web of Science ®Google Scholar
• Gao C, Qiu H, Zeng W, et al. Formation mechanism of anionic surfactant-templated mesoporous silica. Chem Mater. 2006;18:3904–3914.
   Web of Science ®Google Scholar
• Han Y, Zhao L, Ying JY. Entropy‐driven helical mesostructure formation with achiral cationic surfactant templates. Adv Mater. 2007;19:2454–2459.
   Web of Science ®Google Scholar
• Zhang L, Qiao S, Jin Y, et al. Hydrophobic functional group initiated helical mesostructured silica for controlled drug release. Adv Funct Mater. 2008;18:3834–3842.
   Web of Science ®Google Scholar
• Qiu H, Che S. Chiral mesoporous silica: chiral construction and imprinting via cooperative self-assembly of amphiphiles and silica precursors. Chem Soc Rev. 2011;40:1259–1268.
   PubMed Web of Science ®Google Scholar
• Xie J, Qiu H, Che S. Handedness inversion of chiral amphiphilic molecular assemblies evidenced by supramolecular chiral imprinting in mesoporous silica assemblies. Chem Eur J. 2012;18:2559–2564.
   PubMed Web of Science ®Google Scholar
• Slowing II, Vivero-Escoto JL, Wu C-W, et al. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev. 2008;60:1278–1288.
   PubMed Web of Science ®Google Scholar
• Macquarrie DJ, Jackson DB. Aminopropylated MCMs as base catalysts: a comparison with aminopropylated silica. Chem Commun. 1997;1781–1782.
   Web of Science ®Google Scholar
• Reynhardt JP, Yang Y, Sayari A, et al. Polyamidoamine dendrimers prepared inside the channels of pore‐expanded periodic mesoporous silica. Adv Funct Mater. 2005;15:1641–1646.
   Web of Science ®Google Scholar
• Acosta EJ, Carr CS, Simanek EE, et al. Engineering nanospaces: iterative synthesis of melamine‐based dendrimers on amine‐functionalized SBA‐15 leading to complex hybrids with controllable chemistry and porosity. Adv Mater. 2004;16:985–989.
   Web of Science ®Google Scholar
• Lei C, Shin Y, Liu J, et al. Entrapping enzyme in a functionalized nanoporous support. J Am Chem Soc. 2002;124:11242–11243.
   PubMed Web of Science ®Google Scholar
• Vogt M, Kunath K, Dressman JB. Dissolution enhancement of fenofibrate by micronization, cogrinding and spray-drying: comparison with commercial preparations. Eur J Pharm Biopharm. 2008;68:283–288.
   PubMed Web of Science ®Google Scholar
• Dressman J, Reppas C. Drug solubility: how to measure it, how to improve it. Adv Drug Deliv Rev. 2007;59:531–532.
   Web of Science ®Google Scholar
• TanejaShilpi S, Khatri SK. Formulation and optimization of efavirenz nanosuspensions using the precipitation-ultrasonication technique for solubility enhancement. Artif Cell Nanomed Biotechnol. 2016;44:978–984.
   PubMed Web of Science ®Google Scholar
• Sharma AK, Garg T, Goyal AK, et al. Role of microemuslsions in advanced drug delivery. Artif Cells Nanomed Biotechnol. 2016;44:1177–1185.
   PubMed Web of Science ®Google Scholar
• Keck CM, Müller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm. 2006;62:3–16.
   PubMed Web of Science ®Google Scholar
• Müller R, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future. Adv Drug Deliv Rev. 2001;47:3–19.
   PubMed Web of Science ®Google Scholar
• Gupta MN, Kaloti M, Kapoor M, et al. Nanomaterials as matrices for enzyme immobilization. Artif Cells Blood Subst Biotechnol. 2011;39:98–109.
   PubMed Web of Science ®Google Scholar
• Mohammadian F, Eatemadi A. Drug loading and delivery using nanofibers scaffolds. Artif Cell Nanomed Biotechnol. 2017;45:881–888.
   PubMed Web of Science ®Google Scholar
• Kesisoglou F, Panmai S, Wu Y. Nanosizing–oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev. 2007;59:631–644.
   PubMed Web of Science ®Google Scholar
• Hu Y, Wang J, Zhi Z, et al. Facile synthesis of 3D cubic mesoporous silica microspheres with a controllable pore size and their application for improved delivery of a water-insoluble drug. J Colloid Interface Sci. 2011;363:410–417.
   PubMed Web of Science ®Google Scholar
• Hu Y, Zhi Z, Wang T, et al. Incorporation of indomethacin nanoparticles into 3-D ordered macroporous silica for enhanced dissolution and reduced gastric irritancy. Eur J Pharm Biopharm. 2011;79:544–551.
   PubMed Web of Science ®Google Scholar
• Hu Y, Zhi Z, Zhao Q, et al. 3D cubic mesoporous silica microsphere as a carrier for poorly soluble drug carvedilol. Microporous Mesoporous Mater. 2012;147:94–101.
   Web of Science ®Google Scholar
• Li J, Xu L, Yang B, et al. Facile synthesis of functionalized ionic surfactant templated mesoporous silica for incorporation of poorly water-soluble drug. Int J Pharm. 2015;492:191–198.
   PubMed Web of Science ®Google Scholar
• Tzankov B, Yoncheva K, Popova M, et al. Indometacin loading and in vitro release properties from novel carbopol coated spherical mesoporous silica nanoparticles. Microporous Mesoporous Mater. 2013;171:131–138.
   Web of Science ®Google Scholar
• Zhu W, Wan L, Zhang C, et al. Exploitation of 3D face-centered cubic mesoporous silica as a carrier for a poorly water soluble drug: Influence of pore size on release rate. Mater Sci Eng C. 2014;34:78–85.
   PubMed Web of Science ®Google Scholar
• Xu W, Riikonen J, Lehto VP. Mesoporous systems for poorly soluble drugs. Int J Pharm. 2013;453:181–197.
   PubMed Web of Science ®Google Scholar
• Halim Mohamed MA, Mahmoud AA. Formulation of indomethacin eye drops via complexation with cyclodextrins. Curr Eye Res. 2011;36:208–216.
   PubMed Web of Science ®Google Scholar
• Ibrahim HM, Ahmed TA, Lila AEA, et al. Mucoadhesive controlled release microcapsules of indomethacin: Optimization and stability study. J Microencapsul. 2010;27:377–386.
   PubMed Web of Science ®Google Scholar
• Dereymaker A, Scurr DJ, Steer ED, et al. Controlling the release of indomethacin from glass solutions layered with a rate controlling membrane using fluid-bed processing. Part 1: surface and cross-sectional chemical analysis. Mol Pharmaceutics. 2017;14:959–973.
   PubMed Web of Science ®Google Scholar
• Tian B, Tang X, Taylor LS. Investigating the correlation between miscibility and physical stability of amorphous solid dispersions using fluorescence-based techniques. Mol Pharmaceutics. 2016;13:3988–4000.
   PubMed Web of Science ®Google Scholar
• Duong TV, Van Humbeeck J, Van den Mooter G. Crystallization kinetics of indomethacin/polyethylene glycol dispersions containing high drug loadings. Mol Pharmaceutics. 2015;12:2493–2504.
   PubMed Web of Science ®Google Scholar
• Mehta M, Ragoonanan V, McKenna GB, et al. Correlation between molecular mobility and physical stability in pharmaceutical glasses. Mol Pharmaceutics. 2016;13:1267–1277.
   PubMed Web of Science ®Google Scholar
• SahinEsendagli A, Yerlikaya G, Caban-Toktas F, et al. A small variation in average particle size of PLGA nanoparticles prepared by nanoprecipitation leads to considerable change in nanoparticles' characteristics and efficacy of intracellular delivery. Artif Cells Nanomed Biotechnol. 2017. DOI:10.1080/21691401.2016.1276924
   Web of Science ®Google Scholar
• Jahangiri A, Barzegar-Jalali M, Javadzadeh Y, et al. Physicochemical characterization of atorvastatin calcium/ezetimibe amorphous nano-solid dispersions prepared by electrospraying method. Artif Cell Nanomed Biotechnol. 2017;45:1138–1145.
   PubMed Web of Science ®Google Scholar
• Kortesuo P, Ahola M, Karlsson S, et al. Silica xerogel as an implantable carrier for controlled drug delivery –evaluation of drug distribution and tissue effects after implantation. Biomaterials. 2000;21:193–198.
   PubMed Web of Science ®Google Scholar
• Slowing I, Trewyn BG, Lin VSY. Effect of surface functionalization of MCM-41-type mesoporous silica nanoparticles on the endocytosis by human cancer cells. J Am Chem Soc. 2006;128:14792–14793.
   PubMed Web of Science ®Google Scholar
• Wang Y, Han N, Zhao Q, et al. Redox-responsive mesoporous silica as carriers for controlled drug delivery: a comparative study based on silica and PEG gatekeepers. Eur J Pharm Sci. 2015;72:12–20.
   PubMed Web of Science ®Google Scholar
• Zhao P, Wang L, Sun C, et al. Uniform mesoporous carbon as a carrier for poorly water soluble drug and its cytotoxicity study. Eur J Pharm Biopharm. 2012;80:535–543.
   PubMed Web of Science ®Google Scholar